NCT04887519View on ClinicalTrials.gov

A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)

CompletedOBSERVATIONAL
Enrollment

39

Participants

Timeline

Start Date

December 30, 2020

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions
Carcinoma, Non-Small-Cell LungAnaplastic Lymphoma Kinase
Interventions
OTHER

No Intervention

This is a non-interventional study.

Trial Locations (1)

C1055AAD

IC Projects, Buenos Aires

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY